<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00871611</url>
  </required_header>
  <id_info>
    <org_study_id>VIE190109</org_study_id>
    <nct_id>NCT00871611</nct_id>
  </id_info>
  <brief_title>Viennese Prevalence Study of Anderson-Fabry Disease</brief_title>
  <acronym>VIEPAF</acronym>
  <official_title>Prevalence of Anderson - Fabry Disease in Patients With Left Ventricular Hypertrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prevalence of Anderson - Fabry disease in patients with left ventricular hypertrophy is
      unclear. The investigators will examine urine - α - Galactosidase activity and
      globotriaosylceramide isoforms in these patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anderson - Fabry disease (AFD) is a rare, X - linked hereditary systemic lysosomal storage
      disorder which usually affects the heart. The reported incidence of AFD is between 1 in
      117000 and 1 in 240000 live births. Due to a deficiency of the enzyme α - galactosidase,
      glycosphingo-lipids, primarily globotriaosylceramide, are stored also in endothelial and
      myocardial cells, leading to morphologic and functional changes. AFD-cardiomyopathy
      progresses with age and with the course of the disease, leading to reduced life expectancy.
      The investigators hypothesize, that AFD could be underdiagnosed in patients with only mild or
      moderate left ventricular myocardial hypertrophy. Early diagnosis of AFD may be relevant
      since affected patients might benefit from enzyme replacement therapy at early stage of
      disease. The investigators will examine 4000 consecutive patients with an
      echocardiographically measured interventricular septum thickness of ≥ 12mm. Urine samples
      will be collected and Gb3-isoforms, creatinine and α - Galactosidase activity will be
      measured.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">January 2012</completion_date>
  <primary_completion_date type="Anticipated">January 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of Anderson - Fabry disease</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Fabry Disease</condition>
  <condition>Left Ventricular Hypertrophy</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with left ventricular hypertrophy diagnosed by echocardiography
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with myocardial septum wall thickness ≥ 12mm

        Exclusion Criteria:

          -  Patients &lt; 18 years

          -  Patients unable to provide urine sample
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerald Mundigler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna, Dept. Internal Medicine, Cardiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Internal Medicine II, Div. Cardiology, Vienna General Hospital</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <reference>
    <citation>Weidemann F, Breunig F. [Cardiac involvement in Fabry's disease]. Med Klin (Munich). 2008 Mar 15;103(3):161-5. doi: 10.1007/s00063-008-1023-1. Review. German.</citation>
    <PMID>18344066</PMID>
  </reference>
  <reference>
    <citation>Linhart A, Kampmann C, Zamorano JL, Sunder-Plassmann G, Beck M, Mehta A, Elliott PM; European FOS Investigators. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J. 2007 May;28(10):1228-35. Epub 2007 May 5.</citation>
    <PMID>17483538</PMID>
  </reference>
  <reference>
    <citation>Monserrat L, Gimeno-Blanes JR, Marín F, Hermida-Prieto M, García-Honrubia A, Pérez I, Fernández X, de Nicolas R, de la Morena G, Payá E, Yagüe J, Egido J. Prevalence of fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2007 Dec 18;50(25):2399-403.</citation>
    <PMID>18154965</PMID>
  </reference>
  <reference>
    <citation>Fauler G, Rechberger GN, Devrnja D, Erwa W, Plecko B, Kotanko P, Breunig F, Paschke E. Rapid determination of urinary globotriaosylceramide isoform profiles by electrospray ionization mass spectrometry using stearoyl-d35-globotriaosylceramide as internal standard. Rapid Commun Mass Spectrom. 2005;19(11):1499-506.</citation>
    <PMID>15880667</PMID>
  </reference>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2009</study_first_submitted>
  <study_first_submitted_qc>March 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2009</study_first_posted>
  <last_update_submitted>July 27, 2011</last_update_submitted>
  <last_update_submitted_qc>July 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2011</last_update_posted>
  <responsible_party>
    <name_title>Mundigler</name_title>
    <organization>Medical University of Vienna</organization>
  </responsible_party>
  <keyword>Hereditary</keyword>
  <keyword>Anderson-Fabry</keyword>
  <keyword>prevalence</keyword>
  <keyword>heart</keyword>
  <keyword>hypertrophy</keyword>
  <keyword>urine</keyword>
  <keyword>globotriaosylceramide</keyword>
  <keyword>isoforms</keyword>
  <keyword>α - Galactosidase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Fabry Disease</mesh_term>
    <mesh_term>Hypertrophy, Left Ventricular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

